Quarterly Result24 Jul 2026, 02:58 pm
Laurus Labs Q1 FY27 Revenue ₹2,026 Cr, Up 29%
AI Summary
Laurus Labs reported a strong Q1 FY27 with a record revenue of ₹2,026 Crore, marking a 29% year-on-year increase. The company also saw significant growth in EBITDA, which rose by 66% to ₹644 Crore, with EBITDA margins expanding by 7.0% to 31.8%. Gross margins improved by over 3% to 62.7%. This performance was driven by strong commercial deliveries in the CDMO segment, particularly small molecules, and continued strength in the Affordable Medicines portfolio. The company also highlighted strategic advancements, including in-licensing two Antibody Drug Conjugates (ADCs) and securing new land parcels to support long-term growth.
Key Highlights
- Q1 FY27 revenue reached ₹2,026 Cr, a 29% YoY increase.
- EBITDA surged 66% to ₹644 Cr, with margins at 31.8%.
- CDMO segment revenue grew 67%, driven by small molecules.
- Affordable Medicines division saw 10% revenue growth.
- Company continues CAPEX for growth in new modalities and capacity.
Price Impact
More from LAURUSLABS